{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T23:56:06Z","timestamp":1724975766335},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,6,12]],"date-time":"2013-06-12T00:00:00Z","timestamp":1370995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40263-013-0070-1","type":"journal-article","created":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T11:22:00Z","timestamp":1370949720000},"page":"625-636","source":"Crossref","is-referenced-by-count":28,"title":["The Impact of Newer Atypical Antipsychotics on Patient-Reported Outcomes in Schizophrenia"],"prefix":"10.1007","volume":"27","author":[{"given":"A. George","family":"Awad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi N. P.","family":"Voruganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,12]]},"reference":[{"key":"70_CR1","unstructured":"U.S. Food and Drug Administration Guidance for Industry. Patient-Reported Outcome Measures; use in medical product development to support labelling claims, FDA (2006)."},{"key":"70_CR2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0033291797005874","volume":"28","author":"LNP Voruganti","year":"1998","unstructured":"Voruganti LNP, Heselgrave RS, Awad AG, et al. Quality of life measurement in schizophrenia: reconciling the question of subjectivity with the question of reliability. Psychol Med. 1998;28:165\u201372.","journal-title":"Psychol Med"},{"key":"70_CR3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-642-57392-7_3","volume-title":"Zukunftsperspekiven in psychiatries und psychothezapie","author":"AG Awad","year":"2002","unstructured":"Awad AG, Voruganti LNP. The subjective\/objective dichotomy: relevance to nosology, research and management. In: Gaebel W, editor. Zukunftsperspekiven in psychiatries und psychothezapie. Dormstadt: Stienkopff Verlog; 2002. p. 21\u20137."},{"key":"70_CR4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.schres.2006.12.017","volume":"91","author":"PM Wehmeier","year":"2007","unstructured":"Wehmeier PM, Kluge M, Schacht A, et al. Correlation of physician and patient related quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res. 2007;91:178\u201386.","journal-title":"Schizophr Res"},{"key":"70_CR5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/oxfordjournals.schbul.a033477","volume":"26","author":"AG Awad","year":"2000","unstructured":"Awad AG, Voruganti LNP. Intervention research in psychosis: issues related to assessment of quality of life. Schizophr Bull. 2000;26:557\u201364.","journal-title":"Schizophr Bull"},{"key":"70_CR6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0893-133X(01)00263-9","volume":"25","author":"LNP Voruganti","year":"2001","unstructured":"Voruganti LNP, Slomka P, Zabel P, et al. Subjective effect of AMPT-induced dopamine depletion in schizophrenia: Correlation between dysphoric responses and striatal D2 binding ratios in SPECT imaging. Neuropsychopharmacology. 2001;25:642\u201350.","journal-title":"Neuropsychopharmacology"},{"key":"70_CR7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1176\/appi.ajp.157.6.1019","volume":"157","author":"L Haan De","year":"2000","unstructured":"De Haan L, Lavalaye J, Linszend D, et al. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157:1019\u201320.","journal-title":"Am J Psychiatry"},{"key":"70_CR8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.07.012","volume":"88","author":"LNP Voruganti","year":"2006","unstructured":"Voruganti LNP, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia: findings from in vivo SPECT study. Schizophr Res. 2006;88:179\u201386.","journal-title":"Schizophr Res"},{"key":"70_CR9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1017\/S1461145709000327","volume":"5","author":"R Mizrahi","year":"2009","unstructured":"Mizrahi R, Mamo D, Pausion P, et al. The relationship between subjective well-being and dopamine D2 receptors in patients treated with dopamine partial agonist and a full antagonist antipsychotic. Int J Neuropsychopharmacol. 2009;5:715\u201321.","journal-title":"Int J Neuropsychopharmacol"},{"key":"70_CR10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00023210-199504010-00002","volume":"4","author":"AG Awad","year":"1995","unstructured":"Awad AG, Voruganti LNP, Heselgrave RJ. The aim of antipsychotic medications: What are they and are they being achieved? CNS Drugs. 1995;4:8\u201316.","journal-title":"CNS Drugs"},{"key":"70_CR11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1586\/14737167.2.4.347","volume":"2","author":"M Ritsner","year":"2002","unstructured":"Ritsner M, Kurs R. Impact of antipsychotic agents and their side-effects on the quality of life in schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2002;2:89\u201398.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"70_CR12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00023210-200418130-00004","volume":"18","author":"AG Awad","year":"2004","unstructured":"Awad AG, Voruganti LNP. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18:877\u201393.","journal-title":"CNS Drugs"},{"key":"70_CR13","unstructured":"Zacher JL, Holmes JC. Second-generation antipsychotics: a review of recently approved agents and drugs in the pipeline. Formulary. 2012;47:106\u201312"},{"key":"70_CR14","doi-asserted-by":"crossref","unstructured":"Tuanainen A, Wahlbeck K. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev. 2000; (2): CD000966.","DOI":"10.1002\/14651858.CD000966"},{"key":"70_CR15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3810\/pgm.2011.03.2273","volume":"123","author":"L Citrome","year":"2011","unstructured":"Citrome L. Iloperidone, asenapine and lurasidone: a brief overview of three new second-generation antipsychotics. Postgrad Med. 2011;123:153\u201362.","journal-title":"Postgrad Med"},{"key":"70_CR16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.clinthera.2009.07.004","volume":"31","author":"SJ Edwards","year":"2009","unstructured":"Edwards SJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparisons of randomized controlled trials. Clin Ther. 2009;31:1345\u201359.","journal-title":"Clin Ther"},{"key":"70_CR17","unstructured":"Agency for Health Care Research and Quality (AHRQ). First generation versus second generation antipsychotics in adults: Comparative effectiveness. Executive Summary, Publication No. 12\u2014EHC054-EF, 2012. http:\/\/www.effectivehealthcare.ahrg.gov\/reports\/final.cfm ."},{"key":"70_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/11594470-000000000-00000","volume":"30","author":"AG Awad","year":"2012","unstructured":"Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia\u2014an update. Pharmacoeconomics. 2012;30:183\u201395.","journal-title":"Pharmacoeconomics"},{"key":"70_CR19","first-page":"21","volume":"6","author":"AG Awad","year":"1997","unstructured":"Awad AG, Voruganti LNP, Heselgrave RJ. Preliminary validation of a conceptual model to assess quality of life in schizophrenia. Qual Life Res. 1997;6:21\u20136.","journal-title":"Qual Life Res"},{"key":"70_CR20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0032-1301884","volume":"45","author":"Mencaccic on behalf of all investigators","year":"2012","unstructured":"Mencaccic on behalf of all investigators. Efficacy and tolerability of switching to ziprasidone in Italian patients with acute exacerbation of schizophrenia\u2014an open-label study. Pharmacopsychiatry. 2012;45:236\u201340.","journal-title":"Pharmacopsychiatry"},{"key":"70_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-12-1","volume":"12","author":"M-W Huang","year":"2012","unstructured":"Huang M-W, Yang T-T, Ten P-R, et al. Effects of paliperidone extended release on the symptoms and functioning of schizophrenia. BMC Clin Pharmacol. 2012;12:1\u201311.","journal-title":"BMC Clin Pharmacol"},{"key":"70_CR22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/schbul\/sbp037","volume":"37","author":"KP Grootens","year":"2011","unstructured":"Grootens KP, van Vellen NM, Peuskens J, et al. Ziprasidone versus olanzapine in recent-onset schizophrenia and schizoaffective disorder\u2014double-blind randomized controlled trial. Schizophr Bull. 2011;37:352\u201361.","journal-title":"Schizophr Bull"},{"key":"70_CR23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11126-011-9177-z","volume":"82","author":"T Jui-Kang","year":"2011","unstructured":"Jui-Kang T, Wen-Kuo L, For-Wey L. Social interaction and drug attitude effectiveness in patients with schizophrenia. Psychiatr Q. 2011;82:343\u201351.","journal-title":"Psychiatr Q"},{"key":"70_CR24","first-page":"369","volume":"4","author":"H Liu-Seifert","year":"2010","unstructured":"Liu-Seifert H, Osuntokun O, Godfrey J, et al. Patient perspectives on antipsychotic treatments and their association with clinical outcomes. Patient Prefer Adherence. 2010;4:369\u201377.","journal-title":"Patient Prefer Adherence"},{"key":"70_CR25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.schres.2010.03.040","volume":"120","author":"JP Docherty","year":"2010","unstructured":"Docherty JP, Baker RA, Eudicone J, et al. Effect of aripiprazole versus haloperidone on PANSS Prosocial items in early episode patients with schizophrenia. Schizophr Res. 2010;120:199\u2013203.","journal-title":"Schizophr Res"},{"key":"70_CR26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1744-859X-9-35","volume":"9","author":"H Ming-Hong","year":"2010","unstructured":"Ming-Hong H, Wei-Wen L, Shao-Tsu C, et al. A 64-week multicentre, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. Ann Gen Psychiatry. 2010;9:35. doi: 10.1186\/1744-859X-9-35 .","journal-title":"Ann Gen Psychiatry"},{"key":"70_CR27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0030-1248313","volume":"43","author":"J Shoemaker","year":"2010","unstructured":"Shoemaker J, Naber D, Vrifland P, et al. Long-term assessment of asenapine versus olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43:138\u201346.","journal-title":"Pharmacopsychiatry"},{"key":"70_CR28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/JCP.0b013e3181e69042","volume":"30","author":"SM Stahl","year":"2010","unstructured":"Stahl SM, Malla A, Newcomer JW, et al. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. Clin Psychopharmacol. 2010;30:425\u201350.","journal-title":"Clin Psychopharmacol"},{"key":"70_CR29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/YIC.0b013e3283372977","volume":"25","author":"C Canuso","year":"2010","unstructured":"Canuso C, Grinspan A, Kalali A, et al. Medication satisfaction in schizophrenia: a blinded initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol. 2010;25:155\u201364.","journal-title":"Int Clin Psychopharmacol"},{"key":"70_CR30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clinthera.2010.02.003","volume":"32","author":"P Burns","year":"2010","unstructured":"Burns P, Morasini P, Gagnon DD, et al. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of pooled analysis of three phase III trials of paliperidone extended release tablets. Clin Ther. 2010;32:275\u201392.","journal-title":"Clin Ther"},{"key":"70_CR31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S1092852900000249","volume":"14","author":"IR Oliveira de","year":"2009","unstructured":"de Oliveira IR, Elkis H, Gattaz WF, et al. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized study versus haloperidol. CNS Spectr. 2009;14:93\u2013102.","journal-title":"CNS Spectr"},{"key":"70_CR32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/JCP.0b013e3181b2fe22","volume":"5","author":"H Kobayashi","year":"2009","unstructured":"Kobayashi H, Morita K, Takeshi K, et al. Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state. J Clin Psychopharmacol. 2009;5:421\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"70_CR33","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1017\/S1461145709000352","volume":"9","author":"SG Potkin","year":"2009","unstructured":"Potkin SG, Weiden PJ, Loebel AD, et al. Remission in schizophrenia: 196-week double-blind treatment with risperidone versus haloperidol. Int J Neuropsychopharmacol. 2009;9:1233\u201348.","journal-title":"Int J Neuropsychopharmacol"},{"key":"70_CR34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/WNF.0b013e31819a68b5","volume":"32","author":"SW Kim","year":"2009","unstructured":"Kim SW, Shin JS, Kim JM, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol. 2009;32:243\u20139.","journal-title":"Clin Neuropharmacol"},{"key":"70_CR35","unstructured":"Schooler N. Long-term treatment with asenapine versus olanzapine in subjects with predominant persistent negative symptoms of schizophrenia. 2009, Abstract SCR-26-076."},{"key":"70_CR36","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.eurpsy.2008.03.006","volume":"23","author":"D Taylor","year":"2008","unstructured":"Taylor D, Hanssens L, Loze JY, et al. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole versus standard of care, results from the STAR study. J Eur Psychiatry. 2008;23:336\u201343.","journal-title":"J Eur Psychiatry"},{"key":"70_CR37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.psychres.2007.11.012","volume":"161","author":"H Nasralla","year":"2008","unstructured":"Nasralla H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the personal and social performance scale in patients with stable schizophrenia. Psychiatry Res. 2008;161:213\u201324.","journal-title":"Psychiatry Res"},{"key":"70_CR38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YIC.0b013e3282f94905","volume":"4","author":"A Rossi","year":"2008","unstructured":"Rossi A, Vita A, Tiradritti P, et al. Assessment of clinical and metabolic status, and subjective well-being in schizophrenia patients switched from typical to atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol. 2008;4:216\u201322.","journal-title":"Int Clin Psychopharmacol"},{"key":"70_CR39","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.pnpbp.2007.06.029","volume":"31","author":"M Ritsner","year":"2007","unstructured":"Ritsner M, Yorkov V, Ratner Y, et al. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia\u2014a 12-month open-label, flexible-dose naturalistic observational study of patients undergoing usual care. Progr Neuro-Psycho Pharmacol Biol Psychiatry. 2007;31:1470\u20137.","journal-title":"Progr Neuro-Psycho Pharmacol Biol Psychiatry"},{"key":"70_CR40","doi-asserted-by":"crossref","unstructured":"Arang C, Gomez-Beneyto M, Brenlla J, et al. A 6-month prospective observational, naturalistic uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Euro Neropsychopharmacol. 2007;17:456\u201363","DOI":"10.1016\/j.euroneuro.2006.11.007"},{"key":"70_CR41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","volume":"7","author":"R Kerwin","year":"2007","unstructured":"Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients\u2014Schizophrenia Trial of aripiprazole: (STAR) study. Eur Psychiatry. 2007;7:433\u201343.","journal-title":"Eur Psychiatry"},{"key":"70_CR42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.164.3.428","volume":"164","author":"MS Swartz","year":"2007","unstructured":"Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. AM J Psychiatry. 2007;164:428\u201336.","journal-title":"AM J Psychiatry"},{"key":"70_CR43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","volume":"68","author":"JM Kane","year":"2007","unstructured":"Kane JM, Meltzer HY, Carson WH, et al. Aripiprazole for treatment resistant schizophrenia: a double-blind comparison study versus perphenazine. J Clin Psychiatry. 2007;68:213\u201323.","journal-title":"J Clin Psychiatry"},{"key":"70_CR44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eurpsy.2006.06.004","volume":"22","author":"D Kudla","year":"2007","unstructured":"Kudla D, Lambert M, Domin S, et al. Effectiveness, tolerability and safety of aripiprazole in patients with schizophrenia or schizoaffective disorder: results of multicentre observational trial. Eur Psychiatry. 2007;22:195\u2013202.","journal-title":"Eur Psychiatry"},{"key":"70_CR45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.pnpbp.2006.09.015","volume":"31","author":"CI Mitsonis","year":"2007","unstructured":"Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia\u2014an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:373\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"70_CR46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.schres.2005.12.857","volume":"84","author":"R Tandon","year":"2006","unstructured":"Tandon R, Marcus RN, Stock EG, et al. A prospective multicentre randomized parallel-group open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: broad effectiveness study trial with aripiprazole (BETA). Schizophr Res. 2006;84:77\u201389.","journal-title":"Schizophr Res"},{"key":"70_CR47","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1176\/appi.ajp.163.12.2080","volume":"163","author":"RA Rosenbeck","year":"2006","unstructured":"Rosenbeck RA, Leslie D, Sendelar J, et al. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080\u20139.","journal-title":"Am J Psychiatry"},{"key":"70_CR48","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4088\/JCP.v67n0910","volume":"67","author":"GA Philips","year":"2006","unstructured":"Philips GA, Van Brunt DL, Roychowdhury SM, et al. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry. 2006;67:1397\u2013403.","journal-title":"J Clin Psychiatry"},{"key":"70_CR49","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","volume":"162","author":"A Breier","year":"2005","unstructured":"Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162:1879\u201387.","journal-title":"Am J Psychiatry"},{"key":"70_CR50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1017\/S1092852900009342","volume":"9","author":"A Loebel","year":"2004","unstructured":"Loebel A, Siu C, Romanos S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr. 2004;9:357\u201364.","journal-title":"CNS Spectr"},{"key":"70_CR51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-003-1648-y","volume":"171","author":"LNP Voruganti","year":"2004","unstructured":"Voruganti LNP, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berlin). 2004;171:121\u201332.","journal-title":"Psychopharmacology (Berlin)"},{"key":"70_CR52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/archpsyc.1981.01780270073010","volume":"38","author":"T Putten Van","year":"1981","unstructured":"Van Putten T, May PRA, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry. 1981;38:187\u201390.","journal-title":"Arch Gen Psychiatry"},{"key":"70_CR53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","volume":"13","author":"TP Hogan","year":"1983","unstructured":"Hogan TP, Awad AG, Eastwood MR. A self-report predictive of drug compliance in schizophrenia: reliability and discriminative validity. Psychol Med. 1983;13:177\u201383.","journal-title":"Psychol Med"},{"key":"70_CR54","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S0033291700030282","volume":"22","author":"TP Hogan","year":"1992","unstructured":"Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination of two measures. Psychol Med. 1992;22:347\u201352.","journal-title":"Psychol Med"},{"key":"70_CR55","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/19.3.609","volume":"19","author":"AG Awad","year":"1993","unstructured":"Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr bull. 1993;19:609\u201318.","journal-title":"Schizophr bull"},{"key":"70_CR56","doi-asserted-by":"crossref","unstructured":"Awad AG, Voruganti LNP. Neuroleptic dysphoria, comorbid abuse in schizophrenia and the emerging science of subjective tolerability. J Dual Design. 2005;1:83\u201395","DOI":"10.1300\/J374v01n02_06"},{"key":"70_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/erp.10.2","volume":"10","author":"AG Awad","year":"2010","unstructured":"Awad AG. Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. Expert Rev Pharmcoecon Outcomes Res. 2010;10:1\u20134.","journal-title":"Expert Rev Pharmcoecon Outcomes Res"},{"key":"70_CR58","doi-asserted-by":"crossref","unstructured":"Naber DA. Self-rating scale to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life and other clinical variables. Int J Clin Psychopharmacol. 1995; 10(suppl)30: 123\u2013133.","DOI":"10.1097\/00004850-199509003-00017"},{"key":"70_CR59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0920-9964(01)00161-X","volume":"56","author":"LNP Voruganti","year":"2002","unstructured":"Voruganti LNP, Awad AG. Personal evaluation of transitions in treatment (PETiT) a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002;56:37\u201348.","journal-title":"Schizophr Res"},{"key":"70_CR60","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1037\/0033-2909.134.2.270","volume":"134","author":"EA Petall","year":"2008","unstructured":"Petall EA, Cooper H, Robinson C. The effects of choice on intrinsic motivation and related outcomes: a meta analysis of research findings. Psychol Bull. 2008;134:270\u2013300.","journal-title":"Psychol Bull"},{"key":"70_CR61","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1192\/bjp.187.6.529","volume":"187","author":"R Rosenbeck","year":"1005","unstructured":"Rosenbeck R, Stroup S, Keefe RS, et al. Measuring outcome priorities and preferences in people with schizophrenia. Brit J Psychiatry. 1005;187:529\u201336.","journal-title":"Brit J Psychiatry"},{"key":"70_CR62","unstructured":"Awad AG. Antipsychotic medications: how satisfied are our patients? Clear Perspective, Management Issues in Schizophrenia 1999; 2: 1\u20136."},{"key":"70_CR63","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1017\/S0033291705004526","volume":"35","author":"D Rofail","year":"2005","unstructured":"Rofail D, Gray R, Gowrnay K, et al. The development and internal consistency of the satisfaction with antipsychotic scale. Psychol Med. 2005;35:1063\u201372.","journal-title":"Psychol Med"},{"key":"70_CR64","first-page":"321","volume":"29","author":"J Endicott","year":"1993","unstructured":"Endicott J, Nee J, Harrison W, et al. Quality of life enjoyment and satisfaction questionnaire. Psychopharmacol Bull. 1993;29:321\u20138.","journal-title":"Psychopharmacol Bull"},{"key":"70_CR65","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.schres.2010.01.021","volume":"118","author":"MK Vernon","year":"2010","unstructured":"Vernon MK, Revicki DA, Awad AG, et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res. 2010;118:271\u20138.","journal-title":"Schizophr Res"},{"key":"70_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1744-859X-10-18","volume":"10","author":"S Brissos","year":"2011","unstructured":"Brissos S, Molodynski A, Dias VV, et al. The importance of measuring psychosocial functioning in schizophrenia. Ann Gen Psychiatry. 2011;10:1\u20137.","journal-title":"Ann Gen Psychiatry"},{"key":"70_CR67","first-page":"91","volume":"24","author":"M Figueira","year":"2001","unstructured":"Figueira M, Brissos S. Measuring psychosocial outcomes in schizophrenia patients. Curr Opin Psychiatry. 2001;24:91\u20139.","journal-title":"Curr Opin Psychiatry"},{"key":"70_CR68","first-page":"235","volume":"22","author":"RJ Heselgrave","year":"1997","unstructured":"Heselgrave RJ, Awad AG, Voruganti LNP. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neuro Sci. 1997;22:235\u201343.","journal-title":"J Psychiatry Neuro Sci"},{"key":"70_CR69","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/YCO.0b013e328314e144","volume":"21","author":"G Juckel","year":"2008","unstructured":"Juckel G, Morosini PL. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry. 2008;21:630\u20139.","journal-title":"Curr Opin Psychiatry"},{"key":"70_CR70","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/schbul\/sbm169","volume":"35","author":"M Bell","year":"2009","unstructured":"Bell M, Tsang HW, Greig TE, et al. Neurocognition, social cognition, perceived social discomfort and vocational outcomes in schizophrenia. Schizophr Bull. 2009;35:738\u201347.","journal-title":"Schizophr Bull"},{"key":"70_CR71","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/JCP.0b013e3181b5f40b","volume":"29","author":"D Hugh","year":"2009","unstructured":"Hugh D, Nuamah IF, Lim P, et al. Independent effect of paliperidone extended release on social functioning beyond its effects on positive and negative symptoms of schizophrenia: a mediation analysis. J Clin Psychopharmacol. 2009;29:496\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"70_CR72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/oxfordjournals.schbul.a006870","volume":"27","author":"TL Patterson","year":"2001","unstructured":"Patterson TL, Goldman S, McKibbin CL, et al. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27:235\u201345.","journal-title":"Schizophr Bull"},{"key":"70_CR73","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s11136-008-9400-z","volume":"17","author":"T Kawata","year":"2008","unstructured":"Kawata T, Rivicki D. Psychometric properties of the personal and social performance scale (PSP) among individuals with schizophrenia living in the community. Qual Life Res. 2008;17:1247\u201356.","journal-title":"Qual Life Res"},{"key":"70_CR74","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0278-5846(85)90021-1","volume":"9","author":"AG Awad","year":"1985","unstructured":"Awad AG, Hogan TP. Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:585\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"70_CR75","author":"CF Snyder","year":"2011","unstructured":"Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2011;. doi: 10-1007\/s11136-011-0054-x .","journal-title":"Qual Life Res"},{"key":"70_CR76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/11597150-000000000-00000","volume":"5","author":"S Staniszewska","year":"2012","unstructured":"Staniszewska S, Haywood K, Brett J, et al. Patient and public involvement in patient-reported outcome measures: evolution not revolution. Patient. 2012;5:79\u201387.","journal-title":"Patient"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0070-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0070-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0070-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T05:05:51Z","timestamp":1595912751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0070-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,12]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0070-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,12]]}}}